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Atherosclerosis, with its major endpoint events such as 
myocardial infarction (MI) and stroke, is still the leading 
cause of death in both men and women in the Western 
world. The cardiovascular disease was the leading cause of 
death in Serbia and Montenegro in 2002, accounting for 
about 40% of all death cases.1 During the year 2006 more 
than 57% of all deaths in Serbia were caused by cardiovas-
cular diseases (in males 52%; in females 62.8%), according 
to data from the Ministry of Health of the Republic of 
Serbia.2
Angiotensin II (Ang II) has been implicated in the patho-
biology of atherosclerosis and the arterial response to injury 
and restenosis, through mechanisms that include vascular 
hypertrophy, extracellular matrix production, and induction 
of cytokines.3–7 ACE is the key enzyme of the RAS system, 
which converts angiotensin I (Ang I) to Ang II, the main 
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Abstract
Introduction: The ACE I/D polymorphism was mostly investigated in association with intima-media thickness, rarely with 
severe atherosclerotic phenotype. 
Materials and methods: We investigated the association of I/D polymorphism with severe carotid atherosclerosis (CA) 
(stenosis > 70%) in asymptomatic and symptomatic patients undergoing carotid endarterectomy. The 504 patients 
subjected to endarterectomy and 492 healthy controls from a population in Serbia were investigated as a case-control 
study.
Results: The univariate logistic regression analysis revealed ACE DD as a significant risk factor for severe CA (odds 
ratio [OR] = 1.3, 95% confidence interval [CI] 1.0–1.7, p = 0.04). After adjustment for the common risk factors (age, 
hypertension, smoking, and HDL) ACE was no longer significant. However, we found a significant independent influence 
of DD genotype on plaque presence in a normotensive subgroup of patients (OR 1.8, CI 1.2–3.0, p = 0.01, corrected for 
multiple testing). In symptomatic patients D allele carriers were significantly more frequent compared with asymptomatic 
patients (OR 1.6 CI 1.0–2.6, p = 0.05).
Conclusions: Our data suggests that ACE I/D is not an independent risk factor for severe CA. On the other hand, a 
significant independent genetic influence of ACE I/D appeared in normotensive and symptomatic patients with severe 
CA. This should be considered in further research toward resolving the complex genetic background of severe CA 
phenotype.
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effector molecule. It is expressed in endothelial cells of 
normal vessels,8 as well as in functionally different vessel 
types.9 ACE also promotes inflammatory cell production of 
Ang II,10 and induction of premature senescence of smooth 
muscle cells.4 Through its actions, ACE first induces 
endothelial dysfunction, than activates monocytes/mac-
rophages, augments vascular inflammation, and, in doing 
so, enhances the atherogenic process.5 The chronic expo-
sure to high levels of circulating and tissue ACE may pre-
dispose to vascular wall remodelling and changes in its 
diameter and thickness.6 The marked accumulation of tis-
sue ACE and Ang II were shown in inflamed regions of 
plaques prone to rupture.7
The ACE gene has functional insertion/deletion (I/D) 
polymorphism of a 287 bp Alu sequence within intron 16.11 
The ACE DD carriers have higher local levels of ACE and 
that genotype may have a more pronounced effect on ather-
osclerosis due to higher Ang II levels.11,12 The ACE inhibi-
tors could reduce atherogenesis.13 The polymorphisms 
within the RAS genes can affect response to therapy.14 So, it 
was reasonable to investigate functional I/D polymorphism 
in atherosclerotic cardiovascular disorders. Investigation of 
the effect of ACE I/D polymorphism in previous studies has 
been mainly focused on an increased risk of MI and ischae-
mic heart disease15,16 or hypertension.17
Considering carotid atherosclerosis (CA), most of the 
studies investigated ACE I/D polymorphism in association 
with subclinical, intermediate atherosclerotic phenotype, 
intima-media thickness (IMT) with conflicting results. 
Recent meta-analysis based on data from more than 20 
studies, the majority of which were case-control studies, 
revealed moderate positive association of ACE D allele 
with common carotid IMT.18 The association of ACE I/D 
gene polymorphism with severe CA and atherosclerotic 
plaques, as an end-stage atherosclerotic phenotype, is rare. 
Thus, we deliberately included a homogenous group of 
patients with clinically evident severe atherosclerosis, who 
had high grade carotid stenosis (> 70%) and were undergo-
ing carotid endarterectomy. The aim of our study was to 
find whether there is an association of ACE I/D gene poly-
morphism with severe carotid atherosclerosis in asympto-
matic and symptomatic patients undergoing carotid 
endarterectomy among the population of Serbia.
Materials and methods
Study population
In this case-control study, the 504 patients were recruited 
among subjects consecutively admitted for carotid endar-
terectomy to the Vascular Surgery Clinic, Dedinje 
Cardiovascular Institute, and Clinic for the Vascular  and 
Endovascular Surgery Diseases, Clinical Centre of Serbia, 
all of them in Belgrade, Serbia, with evidence of carotid 
plaque presence in the internal or common carotid artery. 
The 492 controls, who underwent clinical, ultrasound and 
ECG examination and did not show any evidence of CA, 
cerebrovascular or cardiovascular disease, chronic inflam-
matory disease, renal failure or diabetes mellitus, were 
recruited from the individuals undergoing annual medical 
check-up at Occupational Medical Centres, Belgrade, 
Serbia.
Ultrasound assessment of bilateral carotid atherosclero-
sis was performed by high-resolution B-mode ultrasound 
applying the same protocol for all participants (Toshiba, 
PowerVision 6000, 7.5 MHz, Riverside, CA, USA or 
Acuson Antares™ system, Siemens, Munich, Germany). 
The ultrasonographers were blinded to genotyping results. 
Division into asymptomatic (never having ischaemic symp-
toms) or symptomatic patients were based on prior clinical 
symptoms: if a patient had suffered an ipsilateral stroke or 
transient ischaemic attack of the carotid territory. 
Classification was based on the clinical history obtained 
from the patients and confirmed by medical records. CT 
scans were obtained from all patients, and imaging studies 
were used to rule out silent infarcts in the asymptomatic 
population. Exclusion criteria for all patients were history 
of previous carotid endarterectomy (possible restenosis), 
carotid kinking, carotid aneurysm, tumours, chronic inflam-
matory diseases, autoimmune disease, or renal failure. 
Patients with atrial fibrillation or highly suspected cardiac 
sources of emboli were excluded from the study to avoid 
confusion between cardiac and carotid sources of ischae-
mic events. For all individuals enrolled in the study a medi-
cal history was completed, including information on 
smoking and drinking habits, presence of diabetes, coro-
nary artery disease, peripheral arterial occlusive disease, 
and drug treatment. Subjects with fasting glucose level of 
≥ 7.0 mmol/L, or taking insulin or oral hypoglycaemic drugs 
were characterized to have diabetes mellitus; those with 
previous myocardial infarction or with stable angina pecto-
ris evaluated by selective coronarography that confirmed or 
revealed coronary artery disease were characterized to have 
coronary heart disease. Peripheral artery disease was diag-
nosed as ankle brachial index lower than 0.75. Hypertension 
was defined as a systolic blood pressure ≥ 140 mm Hg, a 
diastolic blood pressure ≥ 90 mm Hg, or current treatment 
with an antihypertensive drug.
The study was approved by the local research ethics 
committee and each participant gave their written informed 
consent to participate in the study.
Ultrasound assessment of the carotid arteries
After the subject had been placed at rest in a supine position, 
the common carotid artery, bulb, internal carotid artery, and 
external carotid artery on both sides were examined from 
several directions using B mode ultrasonography. Ultrasound 
assessment of the bilateral carotid arteries was performed by 
high-resolution B-mode ultrasound Acuson Antares™ sys-
tem (Siemens, Munich, Germany) and HDL 3500 linear 
transducer (5 to 12 MHz; Philips ATL, Bothell, WA, USA). 
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The degree of the carotid stenosis was calculated using the 
North American Symptomatic Carotid Endarterectomy 
Trial (NASCET) method19 or the European Carotid Surgery 
Trialists Collaborative Group (ECST) method,20 depending 
on the clinic it was performed in. The values for the degree 
of stenosis measured according to NASCET were recalcu-
lated according to a formula which defines the relation 
between the two measurements: % stenosis by ECST = 0·6* % 
stenosis by NASCET + 40%.21 All of the patients included 
in the study had stenosis > 70% according to NASCET, 
which is equivalent to 85% according to ECST.
The highest peak systolic (PSV) and end-diastolic (EDV) 
velocities as well as ICA/ CCA carotid artery ratio were 
recorded. Atherosclerotic plaques were defined as focal 
widening relative to adjacent segments as evidenced by pro-
trusion into the lumen and/or localized roughness with 
increased echogenicity. For ultrasound carotid measure-
ments the intraclass correlation coefficient for inter-rater 
and intra-rater reliability was 0.916 and 0.968, respectively. 
CA was defined as the presence of atherosclerotic plaques in 
the internal or the common carotid artery (ICA/CCA).
Laboratory measurements
Lipid concentrations and glucose levels were determined 
from fresh blood samples after overnight fasting. LDL-
cholesterol (LDLC) levels were calculated using Friedwald’s 
formula.22 All biochemical analyses were routinely per-
formed at the hospital laboratories.
Genetic analysis
Genomic DNA was isolated from whole blood samples col-
lected with EDTA and purified by the proteinase K/phenol 
extraction method,23 or by standardized BloodPrep® DNA 
Chemistry isolation kit (Applied Biosystems, Forester City, 
CA, USA) on the ABI PRISM™ 6100 Nucleic Acid 
PrepStation. The I/D polymorphism was typed by polymer-
ase chain reaction (PCR) on ABI 9700 (Applied Biosystems, 
USA) with the three primer method, as previously 
described.24 The 200 ng of genomic DNA was mixed with 
20 pmol of sense primer 5′ctggagaccactcccatcctttct-3′, 7 
pmol of anti-sense primer 5′gatgtggccatcacattcgtcagat-3′, 
and 1.5 pmol of the third, I allele sense specific primer 
5′tgggaccacagcgcccgccactac-3′. Thermal cycling was per-
formed under the following conditions: initial denaturation 
at 93°C for 60 s, 30 cycles at 93°C for 60 s, 65°C for 90 s, 
and 72°C for 90 s, and final extension at 72°C for 5 min. 
Sense and antisense primers flank 478 and 191 bp-long 
fragments for I and D allele respectively, whereas third 
primer and antisense primer flank the 292 bp-long fragment 
specific for the I allele. Amplification products were sepa-
rated by electrophoresis, in 1.8% (w/v) agarose gels with 
ethidium bromide. The applied electric field was 7.5 V cm−1. 
Bands were visualized by GDS8000 gel documentation 
system (Ultra Violet Products Inc., Upland, USA). At the 
time of genotyping the researchers were completely blinded 
to clinical characterization of samples.
Statistical analysis
Statistical analysis was performed using the Statistica soft-
ware package (Version 5, StatSoft, 1997). Results were 
evaluated by chi-square (χ2), unpaired t-test, and non-para-
metric Mann–Whitney U-test. As a measure of strength of 
association between ACE genotypes and carotid stenosis, 
univariate and multivariate logistic regression analysis was 
used and expressed in terms of adjusted OR and 95% confi-
dence interval (CI). In multivariate regression analysis we 
included the factors that were significantly different in 
patients compared with controls (age, BMI, smoking status, 
hypertension, serum total cholesterol [TC], HDL-cholesterol 
[HDLC], and triglycerides [TG]) and kept covariates in the 
model if the p value of the model was < 0.001. In multiple 
logistic regression analysis carotid plaque presence or pres-
ence of clinical symptoms were entered as the dichotomous 
dependent variable and genotype classes were coded on a 
ratio scale (0 and 1), according to three models of inherit-
ance: model 1 – assumes dominant effect of D allele, model 
2 – recessive effect of D allele, and model 3 – additive effect 
of D allele. In model 1 codes were: 1 for ID + DD and 0 for 
II; in model 2: 1 for DD and 0 for II + ID; in model 3: 0 for 
II, 1 for ID and 2 for DD. Differences with two-tailed alpha-
probability p ≤ 0.05 were considered significant in all tests. 
We used Bonferroni correction in multiple comparisons of 
ACE genotypes between patients and controls.
Results
Description of population
The main characteristics of the patients with severe CA, 
> 70%, and undergoing carotid endarterectomy and controls 
are shown in Table 1. The patients had significantly higher 
BMI, TC, LDLC, and TG values and lower HDLC levels 
compared with the controls. The patients were also signifi-
cantly older and had a significantly higher proportion of 
male individuals, smokers, and individuals who suffered 
from hypertension.
Prevalence of allele and genotype frequencies
The ACE I/D genotype and allele frequencies and odds 
ratio for severe CA, > 70%, in the patients undergoing 
carotid endarterectomy are shown in Table 2. The expected 
genotype frequencies are provided by the control group. 
The genotype frequencies between the patients and the con-
trols were significantly different (χ2 = 8.8, df = 2, p = 
0.012). The DD genotype was significantly more frequent 
among the patients (χ2 = 5.76, df = 1, p = 0.016).
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Association of ACE genotypes with severe CA  
in patients undergoing carotid endarterectomy
We performed both univariate and multivariate analysis of 
association of I/D polymorphism with severe CA, accord-
ing to dominant, recessive, and additive models (see 
Materials and methods). Odd ratios (ORs) for the dose 
dependent effect of D allele according to the additive model 
were significant (Table 2). Significant crude OR for severe 
CA was 1.2 (CI 1.0–1.4) for one D allele and 1.5 (CI 1.1–
2.1) for two D alleles. According to the recessive model OR 
was 1.3 (CI 1.00–1.7) for DD genotype (Table 2). The 
adjusted OR for severe CA was 1.3 (CI 0.8–1.6) for one D 
allele and 1.3 (CI 0.7–2.4) for two D alleles (both p = 0.4). 
Thus, multivariate logistic regression analysis, which 
included common risk factors (age, hypertension, smoking, 
and HDLC) showed that ACE I/D is not an independent 
risk factor for severe CA.
Association of ACE genotypes with biochemical 
parameters that carry risk for atherosclerosis
We looked in the patients group for the association of ACE 
I/D genotypes with biochemical parameters which are com-
monly associated with higher risk for atherosclerosis. In 
patients with severe CA undergoing endarterectomy we did 
not find the association of I/D polymorphism genotypes 
with: lipid status (TC, HDLC, TG, ApoAI, ApoB, Lp(a)) or 
inflammatory (CRP, IL-6, WBC, fibrinogen) parameters 
(data not shown).
Association of ACE genotypes with severe 
CA in the subgroups of patients according 
to hypertension
We divided the tested group of patients according to their 
blood pressure status: normotensive or hypertensive. In the 
normotensive patients, the association between DD geno-
type and severe CA was more pronounced than in the 
tested group as a whole (OR 1.8, CI 1.2–3.0, p = 0.01, 
corrected for multiple testing). The OR remained signifi-
cant after the adjustment according to their age and HDL 
(OR 2.6, CI 1.0–6.7, p = 0.04). The frequencies of ACE 
I/D genotypes in normotensive patients and controls are 
presented in Table 3.
Association of ACE genotypes with clinical 
symptoms in patients with severe CA 
undergoing carotid endarterectomy
We analysed ACE I/D as a risk factor for symptomatic CA 
(ipsilateral stroke or transient ischaemic attack) in patients 
with severe CA subjected to endarterectomy. Genotype 
frequencies in symptomatic patients were II = 15.38%, 
ID = 51.40%, DD = 33.22% and in asymptomatic patients 
II = 22.53%, ID = 46.15, DD = 31.32%. We found that in 
Table 1. Main characteristics of patients with severe CA, > 70%, undergoing carotid endarterectomy, and controls
Parameter Patients Controls p*
N 504 492  
Age, years 62.54 ± 12.58 50.44 ± 13.37 < 0.05
Gender F/M, n (%) 205/299 (40.6/59.3) 245/238 (49.8/50.2) < 0.05**
BMI, kg/m2 26.20 ± 3.16 25.39 ± 3.46 < 0.05
TC, mmol/L  5.89 ± 1.30  5.47 ± 1.26 < 0.01
LDLC, mmol/L  3.78 ± 1.17  3.34 ± 1.10 < 0.01
HDLC, mmol/L  1.15 ± 0.41  1.43 ± 0.39 < 0.01
TG, mmol/L  1.94 ± 1.32  1.56 ± 1.25 < 0.01***
Hypertension, % 83.2 7 < 0.05**
Smokers, % 64.2 52.0 < 0.05**
Values are mean ± SD, for age, Body mass index (BMI), total cholesterol (TC), LDL cholesterol (LDLC), HDL cholesterol (HDLC), and triglycerides (TG).
*Student’s t-test. **c2 test. ***Mann–Whitney U-test.
Table 2. The ACE I/D genotype and allele frequencies and 







Genotype 504 492  
 II  83 (16.5)  96 (19.5) Referent
 ID 246 (48.8) 254 (51.6) 1.2 (1.0–1.4) 0.04
 DD 175 (34.7) 142 (28.9) 1.5 (1.1–2.1) 0.04
Recessive model
DD vs. II + ID 1.3 (1.0–1.7) 0.04
Alelle
 I   0.41   0.45 Referent
 D   0.59   0.55 1.2 (1.0–1.4) 0.05
p: univariate logistic regression. OR for genotypes were calculated  
according to additive model (II vs. ID vs. DD).
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symptomatic patients ACE D allele carriers were signifi-
cantly more present compared with asymptomatic patients 
(OR 1.6, CI 1.0–2.6, p = 0.05, according to the dominant 
model of inheritance, corrected for age, smoking, and 
HDLC).
Discussion
Few studies in various populations have focused on the 
relationship between ACE and early atherosclerotic 
changes, such as carotid IMT, in case/control design and 
large population based design.18,25–27 In those studies, how-
ever, the results are conflicting. In two large population-
based studies in Caucasians25 and Japanese26 ACE D allele 
was not associated with common carotid IMT, while in a 
part of the Rotterdam Study, the association was revealed 
only among the smokers.27 In this study, we have investi-
gated association of ACE I/D polymorphism with severe 
carotid atherosclerosis in the Serbian population.
In this population we found significant crude OR for D 
allele and DD genotype carriage for carotid stenosis over 
70%. We showed that the patients undergoing carotid 
endarterectomy had higher D allele frequency compared 
with the controls. Previous to this study, the ACE gene pol-
ymorphism was investigated only in small study groups, 
with carotid plaques as the phenotype of interest. The 
power of our study (999 subjects) to detect the association 
of DD genotype with an OR 1.3 at the significance level of 
0.05 was 70%. It was shown that ACE D allele/DD geno-
type correlated with internal carotid artery stenosis > 50%, 
or plaque presence in a relatively small group of patients 
(43 patients in a Japanese study28 and 68 patients in a 
Swedish study29). Nevertheless, the frequency of D allele in 
our patients group was similar to the patient group in the 
Swedish study29 as well as to the group in an Italian study.30 
The D allele was also shown to promote the severity of 
coronary atherosclerotic lesions.31 These results, as well as 
ours, suggest the certain influence of ACE polymorphism 
on severe atherosclerotic phenotype. Still, in the whole 
patient group this influence was not independent from 
common risk factors for atherosclerosis such as age, 
hypertension, smoking, and HDLC, similarly to the other 
study.32 However, we found statistically a significant inde-
pendent influence of DD genotype on plaque presence in 
the normotensive subgroup of patients. We previously 
showed that D allele was associated with hypertension in 
males in the Serb population.17 The analysis of the normo-
tensive patients as a separate group revealed an association 
that was not influenced by the possible association of ACE 
with hypertension. The previous clinical study, which used 
multivariate regression analysis, revealed that age was a 
significant risk factor for thicker IMT in normotensive 
patients with moderate to severe CA.33 We corrected the 
OR for age and HDLC and it remained significant. The 
association of DD genotype with plaque presence in 
patients without hypertension could be linked to Ang II 
proinflammatory actions, beside its effects on blood pres-
sure regulation. It is known that many researchers have 
argued that the benefits of ACE inhibitors in stable coro-
nary artery disease are largely independent of their blood 
pressure lowering effects. Carotid artery ACE transcription 
and translation was increased within regions of plaque 
inflammation.3 The ACE DD genotype may have a more 
pronounced effect due to higher local levels of ACE and 
Ang II.11,12 Among our symptomatic patients (ipsilateral 
stroke or transient ischaemic attack) D allele was signifi-
cantly more frequent. Previously it was shown that in sub-
jects who died from coronary heart disease, the frequency 
of D allele was significantly increased compared with 
controls.34
It was of importance to investigate the potential role of 
ACE I/D in severe carotid atherosclerotic phenotype, since 
there is a dualism in human CA defined as the difference 
between early non-stenotic atherosclerosis and advanced 
stenotic atherosclerosis. It is well known that the frequency 
of ACE I/D gene polymorphism is different among world-
wide populations’ origins. Studies on a larger sample 
should be performed to evaluate ACE gene in advanced 
stenotic atherosclerosis in different populations, as had pre-
viously been done for intermediate phenotypes, i.e. IMT. 
The IMT concerns only part of the athero-pathogenic pro-
cess and could represent the remodelling changes in 
response to common vascular risk factors, such as hyper-
tension. The strength of our study lies with the fact that it 
was undertaken on a homogenous group of patients, all of 
them with high grade stenosis > 70%. Still, a relatively 
small number of normotensive patients with severe CA rep-
resent one of the limitations of this study which should be 
overcome in the future by pooling samples or using a meta-
analysis approach. The RAS and its main molecules, such 
as ACE are still in the focus of the research since the ACE 
inhibitors represent one of the great therapeutic success sto-
ries of cardiovascular pharmacotherapy.35
In conclusion, our present data suggests a significant and 
an independent genetic influence of ACE I/D polymorphism 
Table 3. The ACE I/D genotype frequencies in normotensive 














II 16 (18.82)  90 (19.65) 0.03
ID 33 (38.82) 238 (51.97)  
DD 36 (42.35) 130 (28.38)  
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in normotensive and symptomatic patients with severe CA. 
Further studies are needed to confirm our findings in larger 
sample sizes in different populations. The ACE as well 
as other components of RAS should not be excluded from 
further research toward resolving the complex genetic back-
ground of severe CA and towards a more personalized use 
of preventive therapies.
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